Overview

  • Product name

    Anti-uPA antibody [EP6274(2)]
    See all uPA primary antibodies
  • Description

    Rabbit monoclonal [EP6274(2)] to uPA
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, ICC/IFmore details
    Unsuitable for: Flow Cyt,IHC-P or IP
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Chimpanzee
  • Immunogen

    A synthetic peptide corresponding to residues in human PLAU, P00749.

  • Positive control

    • PC3 cell lysate. PC3 cells.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
  • Storage buffer

    Preservative: 0.01% Sodium azide
    Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
  • Purity

    Tissue culture supernatant
  • Clonality

    Monoclonal
  • Clone number

    EP6274(2)
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab169754 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 48 kDa.
ICC/IF 1/50 - 1/100.
  • Application notes
    Is unsuitable for Flow Cyt,IHC-P or IP.
  • Target

    • Relevance

      Urokinase type plasminogen activator (uPA) is secreted from cells as a precursor which is activated to the two chain form consisting of an A and B chain. The active high MW form is further processed by removal of an amino terminal fragment to an active low MW form (35 kDa). uPA is a serine protease that activates plasminogen toplasmin. High levels of uPA and plasminogen activator inhibitor type 1 (PAI 1) in breast cancer tissue extracts have been associated with rapid disease progression. The malignant phenotype of prostatic tumor cells correlates with the expression of both uPA and its cell membrane receptor (uPAR).
    • Database links

    • Alternative names

      • ATF antibody
      • BDPLT5 antibody
      • EC 3.4.21.73 antibody
      • PLAU antibody
      • QPD antibody
      • u PA antibody
      • U plasminogen activator antibody
      • u-PA antibody
      • UPA antibody
      • UPAM antibody
      • Urinary plasminogen activator antibody
      • URK antibody
      • Urokinase plasminogen activator antibody
      • Urokinase type plasminogen activator antibody
      see all

    Images

    • Anti-uPA antibody [EP6274(2)] (ab169754) at 1/1000 dilution + PC3 cell lysate at 10 µg

      Predicted band size: 48 kDa

    • Immunofluorescent analysis of of PC3 cells labeling uPA with ab169754 at 1/50 dilution (green). DAPI nuclear staining (blue).

    References

    This product has been referenced in:

    • Wei L  et al. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacol Res 143:73-85 (2019). Read more (PubMed: 30862605) »
    • Meng D  et al. MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells. Onco Targets Ther 11:7733-7743 (2018). Read more (PubMed: 30464522) »
    See all 8 Publications for this product

    Customer reviews and Q&As

    This product is known to not work in this application or species.
    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Blocking step
    H2O2 as blocking agent for 10 minute(s) · Concentration: 3% · Temperature: 20°C
    Antigen retrieval step
    None
    Sample
    Human Tissue sections (primary invasive breast cancer)
    Specification
    primary invasive breast cancer
    Permeabilization
    No
    Fixative
    Hepes-glutamic acid buffer mediated Organic solvent Protection Effect (HOPE)

    Abcam user community

    Verified customer

    Submitted Apr 02 2014

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up